Cargando…

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression

Investigations into the regulatory mechanisms controlling cholesterol homeostasis have proven fruitful in identifying low-density lipoprotein (LDL)-lowering therapies to reduce the risk of atherosclerotic cardiovascular disease. A major advance was the discovery of proprotein convertase subtilisin/k...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Solingen, Coen, Oldebeken, Scott R., Salerno, Alessandro G., Wanschel, Amarylis C. B. A., Moore, Kathryn J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310920/ https://www.ncbi.nlm.nih.gov/pubmed/34322524 http://dx.doi.org/10.3389/fcvm.2021.667298

Ejemplares similares

LDL Receptor Pathway Regulation by miR-224 and miR-520d
por: Salerno, Alessandro G., et al.
Publicado: (2020)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Editorial: Covid-19 Mechanisms on Cardio-Vascular Dysfunction: From Membrane Receptors to Immune Response
por: Wanschel, Amarylis C. B. A., et al.
Publicado: (2021)

Editorial: COVID-19 mechanisms on cardio-vascular dysfunction: from membrane receptors to immune response, volume II
por: Moretti, Ana Iochabel Soares, et al.
Publicado: (2023)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
por: Duff, Christopher J., et al.
Publicado: (2009)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins
por: Vickers, Kasey C., et al.
Publicado: (2011)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
por: Rymer, Jennifer A., et al.
Publicado: (2020)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
por: Johns, Douglas G., et al.
Publicado: (2023)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

MicroRNAs: New Players in the Pathobiology of Preeclampsia
por: Bounds, Kelsey R., et al.
Publicado: (2017)

SUN-574 A1AT: Novel Inhibitor of Active PCSK9
por: Melendez, Quantil, et al.
Publicado: (2020)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

The Effect of Temperature on the Stability of PCSK-9 Monoclonal Antibody: An Experimental Study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
por: Chen, Hongzhen, et al.
Publicado: (2023)

A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles
por: Sarkar, Samantha K., et al.
Publicado: (2020)

Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
por: Nava-Salazar, Sonia, et al.
Publicado: (2022)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
por: Leucker, Thorsten M., et al.
Publicado: (2018)

Roles of MicroRNAs in Glucose and Lipid Metabolism in the Heart
por: Du, Hengzhi, et al.
Publicado: (2021)

Role of MicroRNAs in the Pathogenesis of Coronary Artery Disease
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

Editorial: MicroRNAs—clinical biomarkers for atrial fibrillation
por: Moscoso, Isabel, et al.
Publicado: (2023)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

SAT-576 Possible Involvement of Thyroid Function in PCSK9 Inhibitor Therapy
por: Iwabuchi, Masayasu
Publicado: (2020)

FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)

Netrin-1 promotes adipose tissue macrophage accumulation and insulin resistance in obesity
por: Ramkhelawon, Bhama, et al.
Publicado: (2014)

The negative regulation of gene expression by microRNAs as key driver of inducers and repressors of cardiomyocyte differentiation
por: Cianflone, Eleonora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g1gfmo56jkm4fflqm91bm5chg9